Free practice quiz
BCPS Prep Course (BCPS): free quiz
10 questions from the program. See your score right away, then unlock the explanation of every answer.
- Question 1 of 10
A 68-year-old adult with atrial fibrillation is admitted for pneumonia. Home medications include warfarin 5 mg by mouth nightly, amiodarone 200 mg by mouth daily, and lisinopril 20 mg by mouth daily. The admitting team starts trimethoprim-sulfamethoxazole DS 1 tablet by mouth twice daily. As the pharmacist reviewing medication problems, which issue should be prioritized first?
Correct Answer
D is correct. TMP-SMX inhibits warfarin metabolism and can cause a rapid INR rise; amiodarone already potentiates warfarin, making this high-priority bleeding risk. This is the most urgent medication problem because it is safety-critical and preventable.
NOTICE: warfarin plus amiodarone plus TMP-SMX. SAY: recommend an alternative antibiotic or empiric warfarin dose reduction with prompt INR follow-up. MONITOR: INR within 2-3 days and bleeding daily. HOLD/CLARIFY/ESCALATE: escalate immediately for active bleeding or supratherapeutic INR.
Why the other options are incorrect
B: tempting because illness can affect ACE inhibitor tolerability, but cough is not the urgent issue; the immediate high-risk interaction is warfarin-TMP-SMX. A: tempting because infection changes therapy, but oral amiodarone does not require IV conversion here. C: tempting if stable outpatient monitoring is assumed, but delayed INR follow-up is unsafe after starting TMP-SMX.
- Question 2 of 10A 79-year-old adult takes metformin 1000 mg by mouth twice daily, gabapentin 300 mg three times daily, and oxybutynin ER 10 mg daily. The pharmacist wants a more sensitive outpatient cognitive screen than a very brief test because mild impairment is suspected despite independent basic ADLs. Which tool is most appropriate?
Why C is correct
The Montreal Cognitive Assessment evaluates several domains, including attention, executive function, recall, language, and visuospatial ability, and is often used when mild cognitive impairment is suspected. For pharmacists, this can clarify whether a regimen with anticholinergic burden, such as oxybutynin, may be worsening cognition.
NOTICE: subtle memory concerns plus an anticholinergic medication. SAY: a more detailed screen may help identify whether medicines are contributing. MONITOR: cognition trend, adherence, and anticholinergic adverse effects. HOLD/CLARIFY/ESCALATE: recommend reassessing oxybutynin if cognitive decline is suspected.
Why the other options are incorrect
B: Braden is for pressure injury risk, not cognition. D: Morse Fall Scale evaluates fall risk, not mild cognitive impairment. A: Katz ADL may remain normal in early cognitive decline and cannot exclude it.
- Question 3 of 10
A 79-year-old woman with advanced heart failure and atrial fibrillation elects comfort-focused care. Current medications are metoprolol succinate 50 mg orally daily, digoxin 0.125 mg orally daily, torsemide 40 mg orally twice daily, and amiodarone 200 mg orally daily. She has marked nausea and bradycardia with heart rate 46 beats/min. Serum creatinine has risen from 1.0 to 1.8 mg/dL. As the pharmacist, which medication is most important to reassess first?
Correct answer: C
Digoxin toxicity should be suspected with nausea, bradycardia, worsening renal function, and concurrent amiodarone, which increases digoxin exposure through P-glycoprotein inhibition. This is especially important in comfort-focused care because preventable toxicity undermines quality of life. Amiodarone and metoprolol can contribute to bradycardia, making them tempting choices, but the renal-interaction trap strongly points to digoxin as the first reassessment target.
Pharmacist Action: NOTICE the triad of renal decline, bradycardia, and nausea on digoxin; SAY, "Digoxin toxicity is a concern, especially with amiodarone"; MONITOR heart rate, symptoms, renal function, and digoxin concentration if appropriate; HOLD/CLARIFY/ESCALATE immediately for severe bradyarrhythmia or visual changes.Why the other options are incorrect
D: Tempting because diuretics can cause dehydration. Eliminating fact: torsemide does not explain the classic digoxin toxicity pattern. A: Tempting due to interaction awareness. Eliminating fact: amiodarone is important, but the medication most directly at risk for toxicity is digoxin. B: Tempting because beta blockers slow rate. Eliminating fact: they are not universally contraindicated in palliative care and may still aid symptoms.
Pharmacist Action: NOTICE drug-interaction clusters rather than single-drug blame; SAY, "We should consider holding digoxin and reassessing the full rate-control regimen"; MONITOR dyspnea and edema if rate-control drugs are adjusted; HOLD/CLARIFY/ESCALATE if hypotension or worsening perfusion occurs. - Question 4 of 10A pharmacist reviews an order for duloxetine 60 mg by mouth once daily in a 59-year-old adult with painful diabetic neuropathy and chronic liver disease from alcohol-associated cirrhosis. Which recommendation is most appropriate?
Why A is correct
Duloxetine is generally avoided in patients with substantial alcohol use history or chronic liver disease because of reported hepatotoxicity and altered metabolism. The issue is not simply dose size; the patient’s underlying liver disease is the key factor that makes avoidance appropriate.
Pharmacist Action: NOTICE duloxetine planned in chronic liver disease. SAY that the agent should generally be avoided because hepatic injury risk is clinically important. MONITOR for alternative neuropathic pain therapy and hepatic symptoms if exposure already occurred. HOLD/CLARIFY/ESCALATE before dispensing when chronic liver disease is documented.Why the other options are incorrect
B: Tempting because duloxetine is effective for neuropathy, but hepatic safety can outweigh benefit here. C: Tempting as a dose-reduction trap, yet lower dosing does not remove the recommendation to avoid. D: Tempting because it is a related class alternative, but SNRIs are not interchangeable with respect to hepatic safety and 225 mg is a high dose.
- Question 5 of 10
An adult with gram-negative bacteremia is receiving gentamicin 7 mg/kg IV every 24 hours in combination with another active agent. Serum creatinine rises from 0.8 to 1.5 mg/dL by day 3. A rapid susceptibility panel now shows the isolate is fully susceptible to ceftriaxone 2 g IV every 24 hours, which the patient is also receiving. As the pharmacist, which recommendation is most appropriate?
Correct Answer: Discontinue gentamicin
Once culture and susceptibility data show ceftriaxone is an appropriate definitive agent, continued gentamicin offers little added benefit and increases nephrotoxicity risk. Continuing or interval-adjusting gentamicin is tempting because aminoglycosides are potent bactericidal drugs, but the key eliminating fact is avoidable toxicity without clear need. Switching ceftriaxone to meropenem is unnecessary because susceptibility already supports de-escalation. Stewardship and safety both favor stopping gentamicin.
NOTICE: Susceptibility data enables narrowing while kidney injury is emerging. SAY: Recommend discontinuing gentamicin and continuing targeted beta-lactam therapy. MONITOR: Serum creatinine daily and clinical response. HOLD/CLARIFY/ESCALATE: Escalate if repeat cultures remain positive or infection source suggests need for broader coverage. - Question 6 of 10A pharmacist reviews repaglinide 1 mg orally three times daily before meals started in a 68-year-old man with type 2 diabetes who takes gemfibrozil 600 mg orally twice daily. Which recommendation is most appropriate?
Correct answer: D
Gemfibrozil strongly inhibits CYP2C8 and can markedly increase repaglinide exposure, causing severe and prolonged hypoglycemia. This interaction is clinically significant enough that the combination should generally be avoided rather than managed with a small dose adjustment.
Pharmacist Action: NOTICE the high-risk interaction at order review; SAY repaglinide should be avoided with gemfibrozil and suggest an alternative glucose-lowering agent; MONITOR blood glucose closely if exposure already occurred; HOLD/CLARIFY/ESCALATE immediately if recurrent hypoglycemia develops.A: Tempting because gemfibrozil is often remembered for statin interactions. Eliminating fact: its CYP2C8 inhibition also strongly affects repaglinide. B: Tempting only from incorrect interaction reasoning. Eliminating fact: the interaction increases repaglinide levels. C: Tempting because some interactions can be managed by lowering the dose. Eliminating fact: this interaction is too large for simple routine coadministration.
- Question 7 of 10
A 63-year-old adult with hypertension, type 2 diabetes, and albuminuric CKD has BP 154/88 mm Hg. Current medications include amlodipine 10 mg PO daily, hydrochlorothiazide 25 mg PO daily, metformin 500 mg PO twice daily, and trimethoprim-sulfamethoxazole DS 1 tablet PO twice daily started yesterday for cystitis. Labs: eGFR 42 mL/min/1.73 m2, potassium 4.6 mEq/L, urine albumin-to-creatinine ratio 420 mg/g. As the clinical pharmacist, which antihypertensive recommendation is most appropriate?
Review Hypertension Drug Selection
B is best: diabetes with albuminuric CKD favors an ACE inhibitor or ARB; losartan 25 mg is a cautious start and potassium/SCr should be checked in 1–2 weeks. D is tempting for albuminuria, but starting 100 mg while on TMP-SMX increases hyperkalemia risk and skips titration. A is similarly kidney-protective, but ACE inhibitor plus TMP-SMX is the interaction trap for hyperkalemia/AKI. C is tempting for resistant hypertension, but spironolactone is later-line and risky with eGFR 42 and K 4.6 before RAAS therapy is optimized.
Pharmacist Action: Notice TMP-SMX + RAAS risk; say recommend antibiotic review and ARB start; monitor BP, SCr, K in 1–2 weeks; hold/clarify if K ≥5.0 or SCr rises ≥30%. - Question 8 of 10
A 71-year-old adult with nonvalvular atrial fibrillation has Child-Pugh class C cirrhosis and is prescribed apixaban 5 mg by mouth twice daily. Serum creatinine is 0.9 mg/dL and weight is 84 kg. As the pharmacist, which recommendation is most appropriate?
Correct answer: Avoid apixaban in severe hepatic impairment
Apixaban is affected by hepatic metabolism, and severe hepatic impairment is a major safety concern because of altered coagulation and uncertain exposure. Product labeling does not recommend use in Child-Pugh class C cirrhosis. The best pharmacist recommendation is to avoid this regimen and discuss an alternative plan with the prescriber.
Why the other options are incorrect
A: Tempting because creatinine is normal. The eliminating fact is that hepatic impairment, not renal function, is the main limitation here. B: Tempting as a dose-reduction strategy. The eliminating fact is that dose reduction does not overcome the severe hepatic impairment warning. D: Tempting because it stays within the DOAC class. The eliminating fact is that rivaroxaban is also problematic in significant hepatic disease and is not chosen for convenience.
Pharmacist Action: NOTICE Child-Pugh class C cirrhosis; SAY this DOAC is not recommended in severe hepatic impairment; MONITOR for bleeding and review baseline liver-related labs; HOLD/CLARIFY/ESCALATE with the prescriber before dispensing.
- Question 9 of 10
A 79-year-old woman with ACS undergoes PCI after receiving aspirin 81 mg PO daily and clopidogrel 75 mg PO daily for several days. The interventional team asks the pharmacist whether prasugrel 10 mg PO daily should be used after a 60 mg load. She weighs 56 kg and has no history of stroke or TIA. Which recommendation is most appropriate?
Correct answer: Consider 5 mg maintenance if prasugrel is used
Prasugrel increases bleeding risk in patients 75 years or older and in those under 60 kg. Although not absolutely contraindicated by age alone, if used in a selected high-risk PCI patient, a 5 mg maintenance dose is generally favored over 10 mg in low-body-weight patients and caution is warranted.
NOTICE age, weight, and stroke history before approving prasugrel; SAY standard 10 mg maintenance is too aggressive for this frail profile; MONITOR bleeding, hemoglobin, and access-site complications daily; HOLD/CLARIFY/ESCALATE if prior stroke/TIA is identified.Why the other options are incorrect
A: Tempting because the patient lacks prior stroke, but 10 mg daily ignores age and weight-related bleeding risk. B: Age over 65 is not the contraindication threshold, and age 75 or older is a caution, not always an absolute prohibition. C: There is no permanent cross-resistance concept that mandates avoiding prasugrel after clopidogrel exposure.
NOTICE dosing traps within the same drug class; SAY prasugrel selection must account for bleeding phenotype, not just ischemic potency; MONITOR for overt and occult bleeding after PCI; HOLD/CLARIFY/ESCALATE if a full-dose regimen is ordered in a high-risk older adult without clear justification. - Question 10 of 10
A pharmacist is asked to recommend an oral add-on to metformin 1000 mg by mouth twice daily for a 67-year-old adult with type 2 diabetes, benign prostatic symptoms, and frequent urination. Which class comparison is most relevant to avoid worsening this symptom burden?
Why A is correct
SGLT2 inhibitors increase urinary glucose excretion, which can lead to osmotic diuresis and increased urinary frequency. In a patient already troubled by lower urinary tract symptoms, this class-specific effect may reduce tolerability and should be weighed against potential cardiorenal benefits.
Pharmacist Action: NOTICE baseline urinary symptoms; SAY this class may worsen frequency and should be chosen only after discussing tradeoffs; MONITOR urinary tolerance, volume status, and infections; HOLD/CLARIFY/ESCALATE if symptoms become intolerable or retention concerns arise.Why C is incorrect
DPP-4 inhibitors are generally well tolerated, so uncommon adverse effects might seem possible. The eliminating fact is that urinary retention via alpha-agonist activity is not a DPP-4 inhibitor effect.
Pharmacist Action: NOTICE fabricated mechanism; SAY DPP-4 inhibitors do not act through adrenergic pathways; MONITOR renal dosing if selected; HOLD/CLARIFY/ESCALATE if misinformation affects consent.Why B is incorrect
Sulfonylureas may seem symptom-neutral. The eliminating fact is that they do not reduce urinary frequency through ADH release and add hypoglycemia risk.
Pharmacist Action: NOTICE invented physiologic effect; SAY choose based on real efficacy and safety features; MONITOR glucose and low-glucose episodes; HOLD/CLARIFY/ESCALATE if meal inconsistency raises risk.Why D is incorrect
Alpha-glucosidase inhibitors are plausible oral alternatives. The eliminating fact is that they do not share SGLT2 cardiorenal outcome benefits and often cause GI adverse effects.
Pharmacist Action: NOTICE benefit overstatement; SAY GI burden must also be considered; MONITOR postprandial glucose if used; HOLD/CLARIFY/ESCALATE if expectations are unrealistic.
See why each answer is right or wrong
Enter your email to unlock the explanation of every question, free.


